Endothelin Signaling as Target for Anticancer Therapy: from Prostate Cancer to Multiple Myeloma
Journal Title: Journal of Oncology and Cancer Research - Year 2018, Vol 2, Issue 1
Abstract
Neuropeptides including endothelin 1 (ET-1) are potent mitogens for both benign and malignant cells through G-protein receptor binding and signal transduction [1]. Aberrant expression of several components of the endothelin axis, including ET-1 and its receptors, ET-A and ET-B is found in various malignancies, including prostate cancer (PC) [1]. Evidence of increased paracrine and autocrine signaling through the endothelin axis in PC cells has triggered clinical testing of ET-1 receptor inhibitors. However, lack of clinical benefit has prevented further development of this approach [2-5]. At the cellular level, we previously reported ET-induced upregulation of proteasome activity and associated proliferative and antiapoptotic effects in androgen-independent PC cells [6]. These effects were reversed with the use of the proteasome inhibitor bortezomib [7]. However, bortezomib failed to demonstrate clinical activity in PC patients, thus its clinical use for inhibiting the endothelin axis could not be supported in that setting [8-11].
Authors and Affiliations
Panagiotis J. Vlachostergios
Keywords
Related Articles
- EP ID EP274751
- DOI 10.28967/jocr.2018.01.18001
- Views 108
- Downloads 0
Appropriate Selection of Segmentectomy for Patients with Early Stage Non-small Cell Lung Cancer
Several randomized-control trials of lung cancer screening, including USA National Lung Cancer Screening Trial (NLST) and Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON), have explored the value of low-dose...
Endothelin Signaling as Target for Anticancer Therapy: from Prostate Cancer to Multiple Myeloma
Neuropeptides including endothelin 1 (ET-1) are potent mitogens for both benign and malignant cells through G-protein receptor binding and signal transduction [1]. Aberrant expression of several components of the endothe...
Evaluation of Phosphorylated Proteins Involved in the Epidermal Growth Factor Receptor (EGFR) Signaling Pathway to Predict the Response of Patients with Breast Cancer to Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel: Preliminary Analysis
This preliminary analysis aimed at evaluating the capacity of epidermal growth factor receptor (EGFR) signaling pathway phosphorylated proteins as predictors of the pathologic response of breast cancer patients treated w...
Effect of Radiotherapy on Antioxidant Vitamin E in Patients with Carcinoma Uterine Cervix- a Pilot Study
Vitamin E, a fat-soluble antioxidant, stops the production of Reactive Oxygen Species (ROS) during the process of fat oxidation. It is used to prevent and repair normal tissue damage and to increase the susceptibility of...
Have Cluster Randomised Trials a Role in Health Care Research?
Cluster Randomised trials, where groups of individuals are randomised to different treatments and outcomes measured on individuals, have many limitations inherent in the trial design. Selection bias can be introduced int...